Literature DB >> 17690845

Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke.

V Lucivero1, M Prontera, D M Mezzapesa, M Petruzzellis, M Sancilio, A Tinelli, D Di Noia, M Ruggieri, F Federico.   

Abstract

Accumulating data suggest that matrix metalloproteinases (MMPs), in particular MMP-2 and MMP-9, are deleterious after acute ischaemic stroke. A beneficial effect of MMPs in the repairing phases of cerebral ischaemia has also been proposed. This study investigated the relationship between MMP-2 and MMP-9 and stroke subtypes, clinical recovery and haemorrhagic transformation (HT). We measured MMP-9 and MMP-2 plasma levels in 29 patients with ischaemic stroke at days one and seven. MMP-2 levels increased only in lacunar strokes, whilst MMP-9 increased only in patients with more severe stroke. Basal MMP-2 levels were higher in patients with stable or recovering symptoms whilst MMP-9 values at day seven were correlated with worse clinical outcome. No differences related to the presence of HT were found. This study sustains a different behaviour of MMPs after ischaemic stroke. MMP-2 seems to be expressed early and related to better outcome, whilst MMP-9 seems to be late and related to more severe stroke.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690845     DOI: 10.1007/s10072-007-0814-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  25 in total

1.  The role of matrix metalloproteinase 9 in early neurological worsening of acute lacunar infarction.

Authors:  Young Seo Kim; Kyu-Yong Lee; Seong-Ho Koh; Chang Yun Park; Hyun Young Kim; Young Joo Lee; Hee Tae Kim; Juhan Kim; Myung-Ho Kim; Kyung Suk Kim; Dae-il Chang; Seung Hyun Kim
Journal:  Eur Neurol       Date:  2006-01-24       Impact factor: 1.710

2.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

Review 3.  Matrix metalloproteinases and free radicals in cerebral ischemia.

Authors:  K Jian Liu; Gary A Rosenberg
Journal:  Free Radic Biol Med       Date:  2005-04-14       Impact factor: 7.376

4.  Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke.

Authors:  J Montaner; J Alvarez-Sabín; C A Molina; A Anglés; S Abilleira; J Arenillas; J Monasterio
Journal:  Stroke       Date:  2001-12-01       Impact factor: 7.914

5.  Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia.

Authors:  M Asahi; X Wang; T Mori; T Sumii; J C Jung; M A Moskowitz; M E Fini; E H Lo
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

6.  Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate.

Authors:  Jérôme Jourquin; Evelyne Tremblay; Nadège Décanis; Gérard Charton; Stephen Hanessian; Anne-Marie Chollet; Thierry Le Diguardher; Michel Khrestchatisky; Santiago Rivera
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

7.  Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke.

Authors:  Joan Montaner; Alex Rovira; Carlos A Molina; Juan F Arenillas; Marc Ribó; Pilar Chacón; Jasone Monasterio; José Alvarez-Sabín
Journal:  J Cereb Blood Flow Metab       Date:  2003-12       Impact factor: 6.200

8.  Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.

Authors:  Joan Montaner; Carlos A Molina; Jasone Monasterio; Sonia Abilleira; Juan F Arenillas; Marc Ribó; Manolo Quintana; José Alvarez-Sabín
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain.

Authors:  G A Rosenberg; E Y Estrada; J E Dencoff
Journal:  Stroke       Date:  1998-10       Impact factor: 7.914

View more
  36 in total

Review 1.  Molecular chaperones in the brain endothelial barrier: neurotoxicity or neuroprotection?

Authors:  Dominique Thuringer; Carmen Garrido
Journal:  FASEB J       Date:  2019-07-26       Impact factor: 5.191

2.  Reliability of the skin blotting method when used on the elderly.

Authors:  Yuiko Koyano; Gojiro Nakagami; Takeo Minematsu; Hiromi Sanada
Journal:  Int Wound J       Date:  2018-06-13       Impact factor: 3.315

Review 3.  Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke.

Authors:  Changjun Yang; Kimberly E Hawkins; Sylvain Doré; Eduardo Candelario-Jalil
Journal:  Am J Physiol Cell Physiol       Date:  2018-10-31       Impact factor: 4.249

4.  Gelatin nanoparticles enhance the neuroprotective effects of intranasally administered osteopontin in rat ischemic stroke model.

Authors:  Elizabeth Joachim; Il-Doo Kim; Yinchuan Jin; Kyekyoon Kevin Kim; Ja-Kyeong Lee; Hyungsoo Choi
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

Review 5.  Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke.

Authors:  Ali Ehsan Sifat; Bhuvaneshwar Vaidya; Thomas J Abbruscato
Journal:  AAPS J       Date:  2017-05-08       Impact factor: 4.009

6.  Heat shock protein 90 inhibition by 17-Dimethylaminoethylamino-17-demethoxygeldanamycin protects blood-brain barrier integrity in cerebral ischemic stroke.

Authors:  Jia Qi; Yan Liu; Ping Yang; Ting Chen; Xin Zhu Liu; You Yin; Jian Zhang; Feng Wang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

7.  Inflammatory and metabolic markers and short-time outcome in patients with acute ischemic stroke in relation to TOAST subtypes.

Authors:  Marcio Francisco Lehmann; Ana Paula Kallaur; Sayonara Rangel Oliveira; Daniela Frizon Alfieri; Franciele Delongui; Johnathan de Sousa Parreira; Maria Caroline Martins de Araújo; Carolina Rossato; Jéssica Tavares de Almeida; Larissa Moliterno Pelegrino; Erick Frank Bragato; Ana Lucia Cruz Fürstenberger Lehmann; Helena Kaminami Morimoto; Marcell Alysson Batisti Lozovoy; Andrea Name Colado Simão; Damácio Ramon Kaimen-Maciel; Edna Maria Vissoci Reiche
Journal:  Metab Brain Dis       Date:  2015-09-11       Impact factor: 3.584

Review 8.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

9.  White matter hyperintensity volume correlates with matrix metalloproteinase-2 in acute ischemic stroke.

Authors:  Zachary A Corbin; Natalia S Rost; Svetlana Lorenzano; Walter N Kernan; Michael K Parides; Jeffrey B Blumberg; Paul E Milbury; Ken Arai; Sophia N Hartdegen; Eng H Lo; Steven K Feske; Karen L Furie
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-01-16       Impact factor: 2.136

Review 10.  Matrix metalloproteinases and peripheral arterial disease.

Authors:  Chiara Busti; Emanuela Falcinelli; Stefania Momi; Paolo Gresele
Journal:  Intern Emerg Med       Date:  2009-07-21       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.